S&P 500   3,849.62 (-0.15%)
DOW   30,937.04 (-0.07%)
QQQ   328.59 (+0.15%)
AAPL   143.16 (+0.17%)
MSFT   232.33 (+1.22%)
FB   282.05 (+1.45%)
GOOGL   1,907.95 (+0.72%)
AMZN   3,326.13 (+0.98%)
TSLA   883.09 (+0.26%)
NVDA   537.41 (-1.60%)
BABA   265.92 (+1.74%)
CGC   35.52 (+7.93%)
GE   11.29 (+2.73%)
MU   79.51 (-2.18%)
AMD   94.71 (+0.62%)
NIO   60.31 (+0.53%)
T   29.75 (+2.20%)
F   11.19 (-0.89%)
ACB   10.67 (+5.02%)
BA   202.06 (-0.64%)
DIS   169.56 (-1.36%)
NFLX   561.93 (+0.92%)
GILD   66.70 (-2.14%)
S&P 500   3,849.62 (-0.15%)
DOW   30,937.04 (-0.07%)
QQQ   328.59 (+0.15%)
AAPL   143.16 (+0.17%)
MSFT   232.33 (+1.22%)
FB   282.05 (+1.45%)
GOOGL   1,907.95 (+0.72%)
AMZN   3,326.13 (+0.98%)
TSLA   883.09 (+0.26%)
NVDA   537.41 (-1.60%)
BABA   265.92 (+1.74%)
CGC   35.52 (+7.93%)
GE   11.29 (+2.73%)
MU   79.51 (-2.18%)
AMD   94.71 (+0.62%)
NIO   60.31 (+0.53%)
T   29.75 (+2.20%)
F   11.19 (-0.89%)
ACB   10.67 (+5.02%)
BA   202.06 (-0.64%)
DIS   169.56 (-1.36%)
NFLX   561.93 (+0.92%)
GILD   66.70 (-2.14%)
S&P 500   3,849.62 (-0.15%)
DOW   30,937.04 (-0.07%)
QQQ   328.59 (+0.15%)
AAPL   143.16 (+0.17%)
MSFT   232.33 (+1.22%)
FB   282.05 (+1.45%)
GOOGL   1,907.95 (+0.72%)
AMZN   3,326.13 (+0.98%)
TSLA   883.09 (+0.26%)
NVDA   537.41 (-1.60%)
BABA   265.92 (+1.74%)
CGC   35.52 (+7.93%)
GE   11.29 (+2.73%)
MU   79.51 (-2.18%)
AMD   94.71 (+0.62%)
NIO   60.31 (+0.53%)
T   29.75 (+2.20%)
F   11.19 (-0.89%)
ACB   10.67 (+5.02%)
BA   202.06 (-0.64%)
DIS   169.56 (-1.36%)
NFLX   561.93 (+0.92%)
GILD   66.70 (-2.14%)
S&P 500   3,849.62 (-0.15%)
DOW   30,937.04 (-0.07%)
QQQ   328.59 (+0.15%)
AAPL   143.16 (+0.17%)
MSFT   232.33 (+1.22%)
FB   282.05 (+1.45%)
GOOGL   1,907.95 (+0.72%)
AMZN   3,326.13 (+0.98%)
TSLA   883.09 (+0.26%)
NVDA   537.41 (-1.60%)
BABA   265.92 (+1.74%)
CGC   35.52 (+7.93%)
GE   11.29 (+2.73%)
MU   79.51 (-2.18%)
AMD   94.71 (+0.62%)
NIO   60.31 (+0.53%)
T   29.75 (+2.20%)
F   11.19 (-0.89%)
ACB   10.67 (+5.02%)
BA   202.06 (-0.64%)
DIS   169.56 (-1.36%)
NFLX   561.93 (+0.92%)
GILD   66.70 (-2.14%)
Log in
OTCMKTS:OREXQ

Orexigen Therapeutics Stock Forecast, Price & News

$0.0053
+0.00 (+35.90 %)
(As of 05/31/2019)
Add
Compare
Today's Range
$0.00
Now: $0.01
$0.01
50-Day Range
$0.01
MA: $0.01
$0.01
52-Week Range
$0.00
Now: $0.01
$0.16
Volume60,300 shs
Average Volume80,439 shs
Market Capitalization$100,101.10
P/E RatioN/A
Dividend YieldN/A
Beta4.98
Orexigen Therapeutics, Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products primarily in the United States, Europe, and South Korea. It offers Contrave for the treatment of obesity. The company also offers Contrave under the Mysimba brand name. Orexigen Therapeutics, Inc. was founded in 2002 and is headquartered in La Jolla, California. On March 12, 2018, Orexigen Therapeutics, Inc., filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

MarketRank

Overall MarketRank

0.44 out of 5 stars

Medical Sector

1629th out of 1,925 stocks

Pharmaceutical Preparations Industry

693rd out of 773 stocks

Analyst Opinion: 0.0Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:OREXQ
CUSIPN/A
Phone858-875-8600
EmployeesN/A
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$33.71 million

Profitability

Miscellaneous

Market Cap$100,101.10
Next Earnings DateN/A
OptionableNot Optionable
$0.0053
+0.00 (+35.90 %)
(As of 05/31/2019)
30 days | 90 days | 365 days | Advanced Chart

Receive OREXQ News and Ratings via Email

Sign-up to receive the latest news and ratings for OREXQ and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Orexigen Therapeutics (OTCMKTS:OREXQ) Frequently Asked Questions

How has Orexigen Therapeutics' stock price been impacted by Coronavirus (COVID-19)?

Orexigen Therapeutics' stock was trading at $0.0053 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, OREXQ stock has increased by 0.0% and is now trading at $0.0053.
View which stocks have been most impacted by COVID-19
.

What stocks does MarketBeat like better than Orexigen Therapeutics?

Wall Street analysts have given Orexigen Therapeutics a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Orexigen Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Who are some of Orexigen Therapeutics' key competitors?

Who are Orexigen Therapeutics' key executives?

Orexigen Therapeutics' management team includes the following people:
  • Mr. Thomas P. Lynch, Consultant (Age 52)

What is Orexigen Therapeutics' stock symbol?

Orexigen Therapeutics trades on the OTCMKTS under the ticker symbol "OREXQ."

How do I buy shares of Orexigen Therapeutics?

Shares of OREXQ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Orexigen Therapeutics' stock price today?

One share of OREXQ stock can currently be purchased for approximately $0.01.

How big of a company is Orexigen Therapeutics?

Orexigen Therapeutics has a market capitalization of $100,101.10 and generates $33.71 million in revenue each year.

What is Orexigen Therapeutics' official website?

The official website for Orexigen Therapeutics is www.orexigen.com.

How can I contact Orexigen Therapeutics?

Orexigen Therapeutics' mailing address is 3344 N. TORREY PINES CT. SUITE 200, LA JOLLA CA, 92037. The company can be reached via phone at 858-875-8600 or via email at [email protected]

This page was last updated on 1/26/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.